You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Active, not recruiting
  • Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
  • +2 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-08
Nov 8, 2021
T
Ropeginterferon Alfa 2b for Early Myelofibrosis
Recruiting
  • Primary Myelofibrosis, Prefibrotic Stage
  • Myelofibrosis
  • Ropeginterferon alfa-2b
  • Hong Kong, Hong Kong
    Department of Medicine, the University of Hong Kong, Queen Mary
2021-07-25
Jul 25, 2021
G
Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis - 2018
Completed
Has Results
  • Primary Myelofibrosis
  • +2 more
  • Rochester, Minnesota
    (unnamed)
2021-08-24
Aug 24, 2021
M
P1101 in Treating Patients With Myelofibrosis
Active, not recruiting
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
  • Laboratory Biomarker Analysis
  • +2 more
  • Scottsdale, Arizona
    Mayo Clinic in Arizona
2022-01-07
Jan 7, 2022
N
Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis
Not yet recruiting
  • Primary Myelofibrosis
  • +2 more
  • (no location specified)
2021-11-05
Nov 5, 2021
S
A Safety and Tolerability Study of Jaktinib
Not yet recruiting
  • Myelofibrosis
  • Jaktinib Hydrochloride Tablet
  • (no location specified)
2022-03-03
Mar 3, 2022
N
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF - 2020
Completed
Has Results
  • Primary Myelofibrosis
  • +2 more
  • Scottsdale, Arizona
  • +8 more
2022-02-10
Feb 10, 2022
N
A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis
Active, not recruiting
  • Primary Myelofibrosis
  • +2 more
  • Jakavi
  • Aachen, Germany
    Novartis Investigative Site
2021-09-06
Sep 6, 2021
F
Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg
Active, not recruiting
  • Myelofibrosis
  • Tours, France
    FILO French Innovative Leukemia Organization
2021-07-19
Jul 19, 2021
N
MAP to Provide Access to Ruxolitinib, for Patients With PMF or PPV MF or PET-MF
Available
  • Primary Myelofibrosis (PMF)
  • +2 more
  • (no location specified)
2022-01-18
Jan 18, 2022
B
A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis - 2020
Withdrawn
  • Primary Myelofibrosis
  • Pacritinib
  • (no location specified)
2021-05-03
May 3, 2021
T
Phase 1b/2 Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
Not yet recruiting
  • Myelofibrosis
  • +3 more
  • (no location specified)
2022-03-05
Mar 5, 2022
I
IMG-7289 in Patients With Myelofibrosis - 2022
Completed
  • Myelofibrosis
  • +3 more
  • Ann Arbor, Michigan
  • +4 more
2022-03-28
Mar 28, 2022
U
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Recruiting
  • Primary Myelofibrosis
  • +2 more
  • Salt Lake City, Utah
    Huntsman Cancer Institute/University of Utah
2021-09-27
Sep 27, 2021
S
Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis
Recruiting
  • Myelofibrosis
  • +3 more
  • Jaktinib hydrochloride tablets
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital of Medical School of Zhejiang Univ
2021-06-11
Jun 11, 2021
N
A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis - 2011
Terminated
Has Results
  • Primary Myelofibrosis
  • +2 more
  • Scottsdale, Arizona
  • +8 more
2021-07-09
Jul 9, 2021
I
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) - 2019
Completed
Has Results
  • Myelofibrosis
  • Winter Park, Florida
  • +17 more
2022-01-10
Jan 10, 2022
J
MPN-RC 118 AVID200 in Myelofibrosis
Active, not recruiting
  • Primary Myelofibrosis
  • +4 more
  • New York, New York
    Icahn School of Medicine at Mount Sinai
2021-05-19
May 19, 2021
C
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Recruiting
  • Primary Myelofibrosis
  • Aomori, Japan
  • +15 more
2022-01-19
Jan 19, 2022
M
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recruiting
  • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-10-30
Oct 30, 2021
N
Study of Select Combinations in Adults With Myelofibrosis
Withdrawn
  • Primary Myelofibrosis
  • +4 more
  • (no location specified)
2021-03-02
Mar 2, 2021
L
A Study of LNK01002 in Patients With Primary (PMF) or Secondary Myelofibrosis (PV-MF, ET-MF) or Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Farmington Hills, Michigan
  • +1 more
2021-06-05
Jun 5, 2021
M
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy - 2022
Completed
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +4 more
  • Eltrombopag Olamine
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-04
Jan 4, 2022
S
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) - 2017
Completed
Has Results
  • Primary Myelofibrosis (PMF)
  • +2 more
  • Phoenix, Arizona
  • +12 more
2021-01-12
Jan 12, 2021
M
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
Recruiting
  • Myelofibrosis Transformation in Essential Thrombocythemia
  • +2 more
  • Elotuzumab
  • Questionnaire Administration
  • Houston, Texas
    M D Anderson Cancer Center
2021-02-17
Feb 17, 2021